aggregates in the ectopic germinal center (GC) of labial salivary glands (LSGs) in SS, speculating that ectopic GC is associated with the autoantibodies production as well as the salivary destruction (5).
We focused on the presence of ectopic GC formation in situ as well as the expression of CXCL 12/CXCL 13. Sixty-four pSS patients were entried and classification of pSS was determined by the revised criteria proposed by the American-European Consensus group (6). LSGs from a control subject who complained of sicca but did not meet the pSS criteria have been obtained. The presence of anti-HTLV-I Ab was determined by enzyme-linked immunosorbent assay (ELISA; Eitest-ATL kit; Esai, Tokyo, Japan) or particle agglutination assay (Serodia-ATL Kit; Fujirebio, Tokyo, Japan). Informed consent for the usage of samples obtained by the biopsy was obtained from all the participating patients as of the commencement of the study, and the study was conducted with the approval of the human ethical committee of our institution. Immunohistochemistry was performed by the labeled streptavidin-biotin method (Histofine Staining Kit, Nichirei Co., Tokyo, Japan) using mouse anti-CXCL 12 monoclonal Ab or goat anti-CXCL 13 polyclonal Ab (R&D Systems Inc., Minneapolis, MN, USA) (2) with microwave epitope retrieval for the detection of CXCL13. Negative control sections were treated with normal Nakamura H et al., Page 3 mouse IgG or normal goat serum. Mann-Whitney's U test, the Chi-square test or Fisher's exact probability test were used for statistical analysis. A P value less than 0.05 was statistically significant.
The gender and age were similar in 32 HTLV-I-seronegative (M/F;3/29, age;56.9 ±14.9) and 32 HTLV-I-seropositive (M/F;4/28, age;58.5 ±12.6) pSS patients, as well as in 9 HTLV-I-associated myelopathy (HAM)-pSS patients (M/F;1/8, age;61.6 ±8.9). Sicca symptoms were observed in 83.3%-100% of patients among the
groups. Differences in anti-SS-A/SS-B Abs (Mesacup SS-A/Ro test and SS-B/La Test;
Medical & Biological Laboratories, Nagoya, Japan) and IgG concentrations at the time of biopsy were not statistically significant irrespective of HTLV-I infection.
Strikingly, ectopic GC was low in HTLV-I-seropositive pSS (1/32, 3.1%) as compared with HTLV-I-seronegative pSS (6/32, 18.8%) (p=0.045), and 0% in HAM-pSS.
Expression of CXCL13 was observed in 0-10 % of MNCs of HTLV-I-seronegative pSS without ectopic GC patients or HTLV-I-seropositive pSS patients (Fig. 1) . In HTLV-I-seronegative pSS (N = 6) with ectopic GC patients, the expression of CXCL13 was found dominantly in the light zone of ectopic GC. All of the cases showed more than 50 % of MNCs in the light zone of ectopic GC expressing CXCL13. One pSS in HTLV-I carrier showed a relatively small size of ectopic GC whose CXCL 13 expression pattern was similar. However, interestingly, the MNCs of HAM-pSS patients demonstrated no expression of CXCL13. In contrast to CXCL 13, CXCL12 was commonly expressed on ductal epithelial cells of all the pSS patients irrespective of anti-HTLV-I Ab. In a normal subject, no expression of CXCL13 was observed with positive expression of CXCL 12 similar with pSS. The lymphoid aggregates of LSGs are responsible for autoantibodies production that is locally occurred in ectopic GC (5, 7, 8) . Radiographic destruction of the ductal structure in HTLV-I-seropositive pSS occurs to a lesser extent than in HTLV-I-seronegative pSS, which is a unique characteristic of the former (4). 
The chemokines have been found to regulate ectopic GC formation of SS (5).
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Key message
Low prevalence of ectopic GC formation is one of the characteristics of HTLV-I-seropositive SS patients associated with CXCL 13 on MNCs. 
